James Investment Research Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 0.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 706,236 shares of the biopharmaceutical company’s stock after buying an additional 3,000 shares during the period. Pfizer makes up about 1.0% of James Investment Research Inc.’s portfolio, making the stock its 16th largest position. James Investment Research Inc.’s holdings in Pfizer were worth $25,622,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Ballew Advisors Inc acquired a new stake in Pfizer in the 1st quarter worth approximately $102,000. Earnest Partners LLC acquired a new stake in Pfizer in the 4th quarter worth approximately $105,000. Woodard & Co. Asset Management Group Inc. ADV acquired a new stake in Pfizer in the 4th quarter worth approximately $118,000. Delpha Capital Management LLC acquired a new stake in Pfizer in the 4th quarter worth approximately $126,000. Finally, W.G. Shaheen & Associates DBA Whitney & Co acquired a new stake in Pfizer in the 1st quarter worth approximately $132,000. 69.14% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE PFE opened at $42.85 on Friday. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41. Pfizer Inc. has a 12 month low of $33.20 and a 12 month high of $42.92. The company has a market cap of $252.46 billion, a price-to-earnings ratio of 14.78, a price-to-earnings-growth ratio of 2.04 and a beta of 0.96.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The business had revenue of $13.47 billion during the quarter, compared to analysts’ expectations of $13.30 billion. During the same period in the previous year, the business posted $0.67 EPS. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. equities research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 4th. Shareholders of record on Friday, August 3rd were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.17%. The ex-dividend date was Thursday, August 2nd. Pfizer’s payout ratio is 51.32%.

In related news, insider Sally Susman sold 40,381 shares of the business’s stock in a transaction on Friday, July 20th. The shares were sold at an average price of $37.22, for a total value of $1,502,980.82. Following the completion of the transaction, the insider now directly owns 155,377 shares in the company, valued at approximately $5,783,131.94. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Laurie J. Olson sold 10,214 shares of the business’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the transaction, the insider now owns 72,672 shares of the company’s stock, valued at $2,979,552. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 761,230 shares of company stock valued at $29,054,690. Company insiders own 0.06% of the company’s stock.

PFE has been the subject of a number of recent analyst reports. Credit Suisse Group set a $39.00 target price on shares of Pfizer and gave the stock a “hold” rating in a research note on Tuesday, July 31st. Goldman Sachs Group reiterated a “neutral” rating and issued a $42.00 target price on shares of Pfizer in a research note on Wednesday, August 1st. Barclays lifted their target price on shares of Pfizer from $38.00 to $40.00 and gave the stock a “neutral” rating in a research note on Thursday, August 23rd. Societe Generale reiterated a “neutral” rating and issued a $39.00 target price on shares of Pfizer in a research note on Wednesday, May 30th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, July 31st. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $41.89.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: Google Finance Portfolio

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.